Aura Biosciences, INC. S-8 Filing
Ticker: AURA · Form: S-8 · Filed: Mar 30, 2026 · CIK: 0001501796
Sentiment: neutral
Filing Stats: 1,193 words · 5 min read · ~4 pages · Grade level 10.5 · Accepted 2026-03-30 07:27:38
Filing Documents
- aura-20260327.htm (S-8) — 132KB
- aura-ex5_1.htm (EX-5.1) — 16KB
- aura-ex23_1.htm (EX-23.1) — 4KB
- aura_exfilingfees.htm (EX-FILING FEES) — 65KB
- img146020637_0.jpg (GRAPHIC) — 2KB
- 0001193125-26-130408.txt ( ) — 370KB
- aura_exfilingfees_htm.xml (XML) — 19KB
Exhibits
Item 8. Exhibits. EXHIBIT INDEX Exhibit No. Description 4.1 Specimen Common Stock Certificate of the Registrant (Incorporated by reference to Exhibit 4.1 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-260156), filed with the Securities and Exchange Commission on October 25, 2021). 4.2 Tenth Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect, as amended by the Certificate of Amendment, dated June 20, 2024 (Incorporated by reference to Exhibit 3.1 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-40971) filed with the Securities and Exchange Commission on August 8, 2024). 4.3 Amended and Restated Bylaws of the Registrant, as currently in effect (Incorporated by reference to Exhibit 3.2 to the Registrant’s Annual Report on Form 10-K (File No. 001-40971) filed with the Securities and Exchange Commission on March 23, 2022). 4.4 Fifth Amended and Restated Investors’ Rights Agreement (Incorporated by reference to Exhibit 4.2 to the Registration Statement on Form S-1 (File No. 333-260156) filed with the Securities and Exchange Commission on October 8, 2021). 4.5 Form of Pre-Funded Warrant to Purchase Common Stock (Incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K (File No. 001-40971) filed with the Securities and Exchange Commission on May 16, 2025). 4.6 Form of Common Stock Warrant to Purchase Common Stock (Incorporated by reference to Exhibit 4.2 to the Registrant’s Current Report on Form 8-K (File No. 001-40971) filed with the Securities and Exchange Commission on May 16, 2025). 5.1* Opinion of Goodwin Procter LLP. 23.1* Consent of Ernst & Young, Independent Registered Public Accounting Firm. 23.2* Consent of Goodwin Procter LLP (included in Exhibit 5.1). 24.1* Power of Attorney (included on signature page). 99.1 2021 Stock Option and Incentive Plan, and f
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Boston, Commonwealth of Massachusetts, on this 30 th day of March, 2026. AURA BIOSCIENCES, INC. By: /s/ Elisabet de los Pinos Name: Elisabet de los Pinos, Ph.D. Title: President and Chief Executive Officer POWER OF ATTORNEY AND SIGNATURES KNOW ALL BY THESE PRESENT, that each individual whose signature appears below hereby constitutes and appoints each of Elisabet de los Pinos, Ph.D., Anthony Gibney and Amy Elazzouzi, as such person’s true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person’s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof. Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following person in the capacities and on the date indicated. Name Title Date /s/ Elisabet de los Pinos President, Chief Executive Officer and Director Principal Executive Officer March 30, 2026